Clinical trial
Risedronate Sodium in Post Menopausal Osteoporosis
NCT00453492 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00453492 |
|---|---|
| Title | Risedronate Sodium in Post Menopausal Osteoporosis |
| Official title | A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoporosis, Postmenopausal |
| Intervention type | Drug |
| Interventions | risedronate sodium |
| Enrollment | 246 |
| Start date | Jan 1, 2004 |
| First posted | Mar 29, 2007 |
| Last update posted | Mar 11, 2008 |
| Countries | Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: